Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

ECT-12003 (S-CITALOPRAM OXALATE)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

90 API Suppliers, 33 USDMF, 18 CEP/COS, 10 JDMF, 18 EU WC, 30 KDMF, 19 NDC API, 40 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

64 Drugs in Development

64 Drugs in Development

INTERMEDIATES

25 Intermediate Suppliers

25 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

617 FDF Dossiers, 84 FDA Orange Book, 276 Europe, 55 Canada, 78 Australia, 44 South Africa, 80 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE, SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 3 Rochem International Inc, 18 SPI Pharma, 7 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 3 Kirsch Pharma, 1 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 21 BASF, 1 CD Formulation, 2 Clariant, 10 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 20 Kerry, 3 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 3 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

69 Fillers, Diluents & Binders, 46 Coating Systems & Additives, 34 Thickeners and Stabilizers, 31 Direct Compression, 28 Solubilizers, 25 Granulation, 24 Controlled & Modified Release, 24 Parenteral, 23 Disintegrants & Superdisintegrants, 23 Film Formers & Plasticizers, 20 Taste Masking, 19 Topical, 19 Chewable & Orodispersible Aids, 13 Lubricants & Glidants, 13 Co-Processed Excipients, 12 Rheology Modifiers, 8 Emulsifying Agents, 6 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 73 Regulatory FDF Prices, 6 Annual Reports

MARKET PLACE

16 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

4 US Exclusivities, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 4 USP, 5 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
06/12/2025	Virupaksha Organics	India	Toru Co., Ltd.	20230823-209-J-1539	Escitalopram Oxalate	2023-08-23	Virupaksha Organics Ltd, Unit-I	India	502 319, Sy.No.10, Gaddapotharam Village, Jinnaram Mandal, Medak District, Andhra Pradesh, lndia.
29/11/2025	Neuland Laboratories	India	Aging Life Science Co., Ltd.	20230919-209-J-1546	Escitalopram oxalate	2023-09-19	Neuland Laboratories Limited	India	Unit-I, Sy. No. 347, 473, 474, 490/2, Bonthapally Village, Veerabhadraswamy Temple Road, Gummadidala Mandal, Sangareddy District - 502313, Telangana State, India.

ECT-12003 (S-CITALOPRAM OXALATE)

ECT-12003 (S-CITALOPRAM OXALATE)

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

90 API Suppliers

33 USDMF

18 CEP/COS

10 JDMF

18 EU WC

30 KDMF

19 NDC API

40 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

64 Drugs in Development

INTERMEDIATES

25 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

617 FDF Dossiers

84 FDA Orange Book

276 Europe

55 Canada

78 Australia

44 South Africa

80 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE

TABLET;ORAL - EQ 20MG BASE

TABLET;ORAL - EQ 5MG BASE

SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

3 Rochem International Inc

18 SPI Pharma

7 DKSH

2 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

1 Pfanstiehl

3 Kirsch Pharma

1 ACG Worldwide

9 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

21 BASF

1 CD Formulation

2 Clariant

10 Corel Pharma Chem

5 DFE Pharma

1 Esteem Industries

2 Finar

10 Gangwal Chemicals

4 Ideal Cures

4 Ingredion Pharma Solutions

20 Kerry

3 Keval Exports

4 Kima Chemical

6 Lonza Capsugel

16 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

7 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

27 Roquette

13 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

3 Silverline Chemicals

3 The Dow Chemical Company

SOLUTION;ORAL - EQ 5MG BASE/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons